- Educational Review
- Open Access
Communicating imaging findings in peritoneal mesothelioma: the impact of ‘PAUSE’ on surgical decision-making
Insights into Imaging volume 12, Article number: 174 (2021)
The peritoneal cavity is the second commonest site of mesothelioma after the pleural cavity. There are five histological types of peritoneal mesothelioma with variable symptomatology, clinical presentation and prognosis. Cystic mesothelioma is a borderline malignant neoplasm with a favourable prognosis, well-differentiated papillary mesothelioma is generally a low-grade malignancy, and all other varieties such as epithelioid, sarcomatoid and biphasic mesothelioma are highly malignant types of peritoneal mesothelioma with poor prognosis. Malignant peritoneal mesothelioma was considered inevitably fatal prior to the introduction of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in selected cases where long-term survival and cure could be achieved. However, the survival benefits following CRS and HIPEC mainly depend on completeness of cytoreduction, which come at the cost of high morbidity and potential mortality. Using the acronym ‘PAUSE’, we aimed at describing the key imaging findings that impact surgical decision-making in patients with peritoneal mesothelioma. PAUSE stands for peritoneal cancer index, ascites and abdominal wall disease, unfavourable sites of involvement, small bowel and mesenteric disease and extraperitoneal disease. Reporting components of ‘PAUSE’ is crucial for patient selection. Despite limitations of CT in accurately depicting the volume of disease, describing findings in terms of PAUSE plays an important role in excluding patients who might not benefit from CRS and HIPEC.
Imaging findings that impacts surgical decision making in peritoneal mesothelioma can be communicated effectively using the acronym PAUSE, which stands for Peritoneal Cancer Index, Ascites and abdominal wall disease, Unfavourable sites, Small bowel and mesenteric disease and Extraperitoneal disease.
CT is the initial modality of choice for evaluating patients with peritoneal mesothelioma.
CT is a good technique for identifying patients with high PCI disease, who may not benefit from CRS and HIPEC.
Peritoneal mesothelioma is a rare condition arising from the mesothelial cells lining the peritoneal cavity. The estimated incidence in men ranges from 0.5 to 3 per million/year and in women ranges from 0.2 to 2 per million/year. The peritoneal cavity is the second commonest site of mesothelioma after the pleura and it is estimated that 10–30% of all cases of mesothelioma occur in the peritoneal cavity [1, 2]. While there is a strong association between asbestos exposure and pleural mesothelioma, with 90% of sufferers having a history, this is only true for around half of those with peritoneal mesothelioma [3,4,5,6]. In addition, it seems that asbestos plays a smaller role in the development of peritoneal mesothelioma in women, only 23% of whom have a history of exposure . Peritoneal mesothelioma also has reported associations with Mediterranean fever; exposure to erionite (a silicate fibre); radiation from thorotrast; papovavirus, simian virus 40; chronic peritonitis and BRCA gene mutations [1, 3, 8, 9].
Peritoneal mesothelioma commonly presents with non-specific symptoms such as abdominal pain and distension [10, 11]. Patients with aggressive subtypes and those with advanced disease may present with rapidly progressing abdominal distension due to large volume ascites, omental disease or intestinal obstruction.
Incidental diagnosis of peritoneal mesothelioma during cross-sectional imaging for other conditions or at laparoscopy, or laparotomy, is not uncommon [10, 12]. Confirmation of the diagnosis is based on histological analysis of biopsies from the peritoneal cavity, obtained either by percutaneous image-guided biopsy, laparoscopy or laparotomy. Cytological analysis of ascitic fluid is of little diagnostic use in most cases . Both the morphological analysis and the immunohistochemistry are crucial for the diagnosis of peritoneal mesothelioma. Immunohistochemical staining is positive for vimentin, calretinin, cytokeratin 5/6 (CK 5/6) and Wilm’s tumour-1 (WT-1), suggesting mesothelial origin, and is typically negative for thyroid transcription factor 1 (TTF 1), BErEP4 antibody, endothelial markers like CD31 and CD34, factor VIII and vascular endothelial growth factor receptor 3 . Loss of expression of BAP1 (BRCA-associated protein 1) has been shown to have high specificity for differentiating peritoneal mesothelioma from benign mesothelial proliferation . Tumour markers such as CA-125, CA15-3, mesothelin and osteopontin may be elevated in patients with peritoneal mesothelioma [15,16,17]. However, these markers are not useful for diagnosis, but may have a role in monitoring for progression or detection of recurrence after surgery.
Histological types and their imaging appearance
There are five main histological types of peritoneal mesothelioma with widely varying clinical behaviour. Cystic mesothelioma is a borderline malignant neoplasm; well-differentiated papillary mesothelioma is a low-grade malignant subtype; and the other types such as epithelioid, sarcomatoid and biphasic subtypes of peritoneal mesothelioma are highly malignant. Desmoplastic, lymphohistiocytoid and deciduoid subtypes of peritoneal mesothelioma are other rare malignant mesothelioma subtypes.
Cystic mesothelioma is a rare neoplasm, estimated to account for 3–5% of peritoneal mesotheliomas and is most commonly found in young and middle-aged women [18, 19]. This entity has many synonyms such as peritoneal inclusion cysts, multicystic peritoneal mesothelioma and benign multicystic mesothelioma. It is increasingly recognised that cystic mesothelioma is a ‘borderline malignancy’ which recurs. The exact pathogenesis of cystic mesothelioma is unknown. Some consider it to be secondary to chronic peritoneal irritation caused by endometriosis, chronic pelvic inflammation or previous surgery . Patients may present with non-specific abdominal pain and tenderness, deep pelvic pain, dyspareunia and urinary symptoms, but in many, the disease is found incidentally and the patient may be totally asymptomatic.
CT and MRI are the modalities of choice for imaging cystic mesothelioma. The radiological appearances are non-enhancing, thin-walled multi-loculated cystic lesions, usually centred in the pelvis and para-colic gutters and typically the cysts surround the pelvic organs (Fig. 1) [21,22,23]. In some cases, cystic lesions may be seen diffusely in the peritoneal cavity with more than half showing lesions in the small bowel mesentery and the greater omentum (Fig. 2) . Calcification of the cyst walls (Fig. 3) has been rarely reported . The differential diagnoses for cystic mesothelioma include lymphangioma, mesenteric and omental cysts, cystic ovarian masses, pseudomyxoma peritonei, endometrioma and peritoneal hydatidosis. As a rare entity, pre-operative diagnosis of cystic mesothelioma is seldom made except in specialised centres and histological evaluation is required to confirm the diagnosis.
Well-differentiated papillary peritoneal mesothelioma
Well-differentiated papillary mesothelioma is uncommon and is seen mainly in females. This subtype has no clear association with asbestos, although anecdotally some patients give a history of asbestos exposure, and it has an indolent clinical course and a favourable prognosis [25, 26]. More than half of the patients with this variant have peritoneal-based masses less than 1 cm in size, which are mostly detected incidentally, either during surgery or on imaging performed for other unrelated causes . Imaging findings range from large volume ascites, omental caking and nodular or plaque-like peritoneal thickening (Fig. 4). Nodular calcifications can be seen in this subtype [25, 28].
Malignant peritoneal mesothelioma
Malignant peritoneal mesothelioma is more common among older men, in their fifth and sixth decades and has a strong association with asbestos exposure. Epithelioid, sarcomatoid and mixed or biphasic mesothelioma are the malignant histological subtypes of peritoneal mesothelioma. Malignant peritoneal mesothelioma tends to spread in a sheet-like fashion along the visceral and the parietal peritoneal surfaces and subsequently becomes confluent, encasing the abdominal viscera. Imaging findings reflect this nature of spread. Based on the predominant imaging findings, malignant peritoneal mesothelioma has been classified as a ‘dry’ painful type, which presents with peritoneal masses (Fig. 5), and a ‘wet’ type, which presents with ascites, omental and peritoneal thickening (Fig. 6) .
Epithelioid mesothelioma is the commonest subtype of peritoneal mesothelioma . This is a steadily progressive, malignant type with varied imaging findings depending on the severity of disease at the time of diagnosis. Typical imaging findings of epithelioid peritoneal mesothelioma constitute ascites, omental caking, diffuse plaque-like parietal and visceral peritoneal thickening, mesenteric nodules and mesenteric fold thickening (Fig. 7). With increase in severity of malignant peritoneal mesothelioma, there is progressive thickening of the visceral and parietal peritoneum, which eventually encases the solid intra-abdominal organs and the bowel, giving rise to a rind of soft tissue surrounding these structures (Fig. 15).
Sarcomatoid mesothelioma is the most aggressive form of peritoneal mesothelioma with a rapidly progressive clinical course. This subtype is more common in elderly patients in their sixth and seventh decades with a slight male predominance. It is rare in the peritoneal cavity. Sarcomatoid peritoneal mesothelioma presents with large peritoneal-based masses, which can be either localised (Fig. 8) or diffuse . Mixed or biphasic mesothelioma has features of both epithelioid and sarcomatoid subtypes (Fig. 9).
Treatment of peritoneal mesothelioma
Cystic mesothelioma usually has a slowly progressive clinical course with some reports that it can rarely transform into malignant mesothelioma . The treatment of choice is total surgical excision. However, following total excision the recurrence rates are high, in the range of 45–50% [18, 32]. Due to the local recurrence rates and the rare possibility of malignant transformation, cystic mesothelioma has been rightly reclassified as a borderline malignant neoplasm. For this reason, many centres have adopted an aggressive therapeutic approach, combining CRS with HIPEC to treat cystic mesothelioma with a reported reduction in recurrence rates to 16.7% and significantly improved 5- and 10-year disease-free survival rates for these patients [4, 33].
Treatment of malignant peritoneal mesothelioma is challenging. The diffuse nature of disease means that it is not amenable to radiotherapy as treatment. Following chemotherapy with platinum-based agents, like cisplatin and gemcitabine as used for pleural mesothelioma, the median survival rate is between 6 and 9 months . Median survival rates have improved to 12.1–26.8 months when platinum agents are combined with pemetrexed, but toxicity is high and response rates are poor [34,35,36]. For these reasons, loco-regional treatment of the peritoneal cavity with cytoreductive surgery and HIPEC has been proposed and utilised as a treatment for peritoneal mesothelioma. Studies in specialised centres have reported superior survival benefits of CRS and HIPEC, when compared with systemic chemotherapy, with an overall median survival of 53 months and 1-, 3- and 5-year survival rates after CRS and HIPEC of 81%, 60% and 47%, respectively [35, 37].
The aim of cytoreductive surgery is to remove all visible tumour from the abdominal cavity, or, in other words, to achieve complete cytoreduction. This is achieved by stripping the involved peritoneum (left and right parietal, left and right diaphragmatic and pelvic), performing a liver capsulectomy, an omentectomy and by removing any visible tumour nodules from the mesentery. Involved non-vital viscera are also removed and may include the colon, rectum, ovaries and uterus, gall bladder, spleen or the stomach. Cytoreduction is followed by HIPEC, during which heated chemotherapy is infused into the abdominal cavity for 60–90 min, either by an open (Fig. 10) or a closed technique. Cytoreductive surgery is a major undertaking with an operative mortality of 0.6–4.4% and a morbidity of 7–49%, even in high volume centres . Surgery lasts around 9 h on an average and patients need multidisciplinary support including intensive care. Many patients will require a temporary or permanent stoma. Achieving complete cytoreduction is key to successful outcome [11, 37,38,39,40,41,42,43]. Incomplete cytoreduction is associated with poor outcomes and negates the benefits of such a high-risk procedure in most cases. Non-invasive imaging plays an important role in the pre-operative assessment of these patients by identifying disease extent, involvement of key anatomic structures which affect operability and the likelihood of achieving complete cytoreduction.
Role of imaging in the surgical decision-making
The main role of imaging in assessing patients with peritoneal mesothelioma is to estimate the overall disease burden. Optimal radiological staging helps in assessing patients’ suitability for surgery and prognosis. Methodical assessment for key anatomical structures on imaging is helpful for selecting patients who may potentially benefit from cytoreductive surgery and HIPEC and estimating the extent of the surgery needed. The acronym ‘PAUSE’ has been proposed to summarise the key imaging findings which radiologists must report in a patient with peritoneal malignancy . In this review, we use this concept to elaborate the findings which impact surgical decision-making in patients with peritoneal mesothelioma. The term 'PAUSE' incorporates the following: P, primary tumour and peritoneal carcinomatosis index (PCI); A, ascites and abdominal wall involvement; U, unfavourable sites of involvement; S, small bowel and mesenteric disease; E, extra peritoneal metastases.
P—peritoneal cancer index (PCI)
The peritoneal cancer index (PCI) was designed, and validated, as a method of estimating the tumour burden during laparotomy and thus was not initially used for case selection . However, PCI closely relates to prognosis of virtually all peritoneal malignancies and correlates with the success of CRS and HIPEC [29, 30, 43]. PCI is a sum of scores obtained from the longest measurement of the largest peritoneal-based lesion in the thirteen anatomical sites of the peritoneal cavity (Fig. 11). The lesions are given a score of 1–3 based on size: 1 if < 0.5 cm, 2 if 0.5–5 cm and 3 if > 5 cm. Imaging is now widely used to pre-operatively estimate the radiological PCI and thus help in patient selection for CRS and HIPEC.
The PCI cut-off for survival benefits largely depends on the histological subtype of peritoneal mesothelioma. For example, PCI estimation is less relevant in determining the outcome of cystic mesothelioma which has a favourable outcome despite its extent. On the other hand, the outcome of malignant peritoneal mesothelioma closely relates to the PCI. Based on a multicentre study, a novel TNM staging was proposed for patients with malignant peritoneal mesothelioma. In this method, the authors propose T-staging of peritoneal mesothelioma based on PCI with PCI of 1–10, 11–20, 21–30 and 30–39 being T1 to T4 stages, respectively . Based on this staging, the 5-year survival of patients with stage I (T1, N0, M0), II (T2/T3, N0, M0) and III (T4, N1, M1 or any T, N1, M1) malignant peritoneal mesothelioma was 87%, 53% and 29%, respectively. This illustrates the importance of PCI in patients with peritoneal mesothelioma and provides a rationale for pre-operative assessment of radiological PCI.
CT is the most widely used imaging modality for estimating radiological PCI. However, CT underestimates PCI and has been reported by some to be only half of that found at surgery . Moreover, CT has poor sensitivity for detecting small peritoneal nodules less than 0.5 cm . Despite these limitations, CT remains the modality of choice for the initial evaluation of patients with peritoneal mesothelioma since it is often the index investigation. A radiological study of 59 patients with peritoneal mesothelioma showed significantly higher rPCI (34 vs. 17), large volume upper abdominal disease, small bowel and mesenteric disease among patients who had incomplete cytoreduction for malignant peritoneal mesothelioma compared to those who had complete cytoreduction . CT or MRI-derived rPCI of ≥ 30 was associated with worse survival and rPCI of ≤ 19 was associated with improved survival in another study of 53 patients with malignant peritoneal mesothelioma . Thus, CT is a good technique for identifying patients with high PCI disease, who may not benefit from CRS and HIPEC.
The CT protocol should include intra-venous contrast enhanced CT of the chest, abdomen and pelvis with thin Sections (1–2 mm) CT of the abdomen and pelvis in the portal venous phase. We advocate positive oral contrast given 1.5 h prior to the study in order to opacify the small bowel. High-quality focussed MRI may be superior to CT in detecting peritoneal disease and can estimate PCI with 88–91% accuracy [47, 48]. However, long scan time, patient-related contra-indications and capacity issues limit the wider usage of MRI in many patients. After an initial assessment with CECT, MRI is usually done in select patients who might be candidates for surgery. MRI is performed with the view to detecting disease which may be missed on CT. But in patients who undergo laparoscopic biopsy, the surgeon would use this opportunity to assess the disease burden and MRI will not add to the management in these patients unless adhesions prelude optimal laparoscopic inspection of the peritoneal cavity. The role of PET-CT in estimating PCI is unclear but in our experience is of limited value [50, 51].
A—abdominal wall involvement and ascites
Spread of peritoneal mesothelioma to the abdominal wall is not a definite contraindication for surgery. However, this may negatively impact on the surgery required and outcome after surgery. Port-sites; drain sites; surgical wounds and scars are common locations of abdominal wall disease . While midline (Fig. 12a) abdominal wall lesions can be easily excised, lateral (Fig. 12b) abdominal wall lesions are problematic and often incurable due to the nature of the abdominal wall lympho-vascular supply. Also, adhesions between the bowel loops and the abdominal wall lesions can compromise the view during diagnostic laparoscopy precluding optimal assessment of disease and increasing the risk of entero-cutaneous fistula. Overall, abdominal wall lesions increase the morbidity of cytoreductive surgery and complex reconstructive techniques may be needed to close the abdomen .
Unlike the malignant ascites from peritoneal carcinomatosis, ascites from peritoneal mesothelioma does not directly impact on the surgery or the outcome. However, complications of ascites such as weight loss, protein malnutrition, renal failure and spontaneous bacterial peritonitis can adversely affect outcome .
Irrespective of the peritoneal cancer index (PCI), involvement of certain anatomic structures by disease negatively impacts on surgery and outcome. We have labelled disease in these key anatomic sites as ‘unfavourable’. For ease of communication, we have further scored these sites as U0, U1 and U2 sites based on impact on management (Table 1) . U0 indicates that no unfavourable sites are detected on imaging and thus complete cytoreduction may be feasible. Involvement of U1 category sites on imaging suggests that cytoreductive surgery may still be possible; however, a more complex surgical procedure should be anticipated. Disease at U2 sites suggests that complete cytoreduction is unlikely to be achieved. Figures 13, 14, 15, 16, 17 and 18 show examples of malignant peritoneal mesothelioma demonstrating disease in one or more unfavourable sites. Careful radiological review aimed at identifying disease in unfavourable sites during MDT discussions is critical for choosing patients who would benefit from cytoreductive surgery and for planning the surgery .
S—small bowel and mesentery
The limiting factor in achieving complete cytoreduction is commonly extensive involvement of the small bowel and mesentery. While focal or regional disease in the small bowel and mesentery may be amenable to complete cytoreduction, this is unlikely when there is multi-focal or diffuse small bowel and mesenteric disease [21, 55, 56]. CT is the most common initial imaging modality used for assessing patients with peritoneal mesothelioma. However, it has been reported that CT has poor overall accuracy of only 21–25% for detecting small bowel and mesenteric disease compared to 92% for MRI [47, 48]. This is mainly because diffuse plaque-like and miliary disease is more often missed on CT (Fig. 19) and CT has poor sensitivity for nodules smaller than 0.5 cm . Thus, in patients being considered for cytoreductive surgery of curative intent, most centres resort to pre-operative diagnostic laparoscopy to complement CT and some perform MRI in patients with inconclusive CT, in order to exclude subtle diffuse small bowel and mesenteric disease.
During CT examination, the use of oral contrast, either neutral or positive, is useful for delineating disease in the small bowel or mesentery. In our experience, the use of positive oral contrast is most useful in identifying small bowel and mesenteric disease, especially in a setting of diffuse peritoneal disease with predominantly isodense or hypodense peritoneal disease. When large soft tissue masses are the predominant finding, the use of neutral contrast medium may be sufficient to allow appreciation of bowel wall enhancement and thickening.
The earliest findings of small bowel and mesenteric disease, detected on CT, are kinking of the small bowel loops, distortion of the bowel lumen and subtle bowel wall thickening. With extensive disease, there are soft tissue masses in the mesentery; mesenteric fold thickening and nodularity; tethering of the mesentery which progresses to stellate mesenteric retraction; eccentric/concentric bowel wall thickening; a rind of soft tissue around the bowel due to diffuse visceral peritoneal thickening and segmental small bowel obstruction (Figs. 14, 15 and 16) . In patients with findings pointing to extensive small bowel and mesenteric disease, complete cytoreduction is unlikely to be achieved and these findings constitute U2 disease . In a study describing the utility of CT for selecting patients for cytoreductive surgery in patients with peritoneal mesothelioma, Yan et al. classified degree of small bowel and mesenteric disease as class I, II and III based on similar imaging findings . Class 1 disease had only ascites; bowel wall thickening and mesenteric soft tissue masses were categorised as class II disease; and complete loss of mesenteric architecture and bowel obstruction constituted class III findings .
In contrast to malignant peritoneal mesothelioma, in patients with cystic mesothelioma, the multi-loculated cystic lesions seen in the omentum, the small bowel and the mesentery are usually free lying lesions which are amenable for surgical excision. Thus, CT findings suggestive of small bowel and mesenteric involvement should only be applied to patients with malignant peritoneal mesothelioma .
Extra-peritoneal spread of peritoneal malignancy is suggestive of systemic spread and advanced stage. Malignant peritoneal mesothelioma is known to metastasise to the lymph nodes (Fig. 20), pleural cavity (Fig. 21), pericardium, lungs and liver and these are considered as significant extra-peritoneal disease . PET-CT has an important role in helping to exclude significant extra-peritoneal disease in patients who are being considered for cytoreductive surgery [50, 58].
Structured reporting of peritoneal malignancy
In a large multi-centric UK-wide peritoneal malignancy MDT, 155 patients with peritoneal mesothelioma were reviewed between 2016 and 2018. In this series, imaging played an important role in decision-making at the MDT and presence of unfavourable disease sites and small bowel or mesenteric disease preluded surgery. Twenty-two (14.2%) patients underwent CRS and HIPEC and 19 had complete cytoreduction . The median surgical PCI of operated patients was 17, which was similar to the median rPCI found in a previous imaging study among patients who underwent complete cytoreduction [21, 55]. Operated patients had better survival outcomes compared to those treated with systemic chemotherapy. Though correlation between ‘PAUSE’ and the outcome is yet to be determined, structured reporting with a score given to each component of ‘PAUSE’ as in Table 2 can be an effective means of communicating and objectively documenting imaging findings in an MDT setting.
Radiology has a crucial role in aiding surgical decision-making. ‘PAUSE’ was designed with a focus on key elements determining feasibility, prognosis and potential benefits from cytoreductive surgery and HIPEC. Using ‘PAUSE’ and several examples of peritoneal mesothelioma, we emphasise key imaging features which should be included in radiology reports on patients with known or suspected peritoneal malignancy.
Availability of data and materials
Data are included in the manuscript.
Hyperthermic intraperitoneal chemotherapy
Malignant peritoneal mesothelioma
Major tumour debulking
Radiological peritoneal cancer index
Boffetta P (2007) Epidemiology of peritoneal mesothelioma: a review. Ann Oncol 18:985–990. https://doi.org/10.1093/annonc/mdl345
Salo SA, Ilonen I, Laaksonen S, Myllärniemi M, Salo JA, Rantanen T (2017) Epidemiology of malignant peritoneal mesothelioma: a population-based study. Cancer Epidemiol 51:81–86. https://doi.org/10.1016/j.canep.2017.10.008
Antman KH, Pomfret EA, Aisner J, MacIntyre J, Osteen RT, Greenberger JS (1983) Peritoneal mesothelioma: natural history and response to chemotherapy. J Clin Oncol 1:386–391. https://doi.org/10.1200/JCO.1918.104.22.1686
Brigand C, Monneuse O, Mohamed F et al (2006) Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study. Ann Surg Oncol 13:405–412. https://doi.org/10.1245/ASO.2006.05.041
Spirtas R, Heineman EF, Bernstein L et al (1994) Malignant mesothelioma: attributable risk of asbestos exposure. Occup Environ Med 51:804–811. https://doi.org/10.1136/oem.51.12.804
Roggli VL, Sharma A, Butnor KJ, Sporn T, Vollmer RT (2002) Malignant mesothelioma and occupational exposure to asbestos: a clinicopathological correlation of 1445 cases. Ultrastruct Pathol 26:55–65. https://doi.org/10.1080/01913120252959227
Gibbs AR (2007) Tumours of the serosal membranes. Armed forces institute of pathology atlas of tumour pathology, fourth series, fascicle 3. Occup Environ Med 64:288. https://doi.org/10.1136/oem.2006.030155
Sekido Y (2013) Molecular pathogenesis of malignant mesothelioma. Carcinogenesis 34:1413–1419. https://doi.org/10.1093/carcin/bgt166
Gazdar AF, Carbone M (2003) Molecular pathogenesis of malignant mesothelioma and its relationship to simian virus 40. Clin Lung Cancer 5:177–181. https://doi.org/10.3816/CLC.2003.n.031
García-Fadrique A, Mehta A, Mohamed F, Dayal S, Cecil T, Moran BJ (2017) Clinical presentation, diagnosis, classification and management of peritoneal mesothelioma: a review. J Gastrointest Oncol 8(5):915–924. https://doi.org/10.21037/jgo.2017.08.01
Magge D, Zenati MS, Austin F et al (2014) Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis. Ann Surg Oncol 21:1159–1165. https://doi.org/10.1245/s10434-013-3358-y
Acherman YIZ, Welch LS, Bromley CM, Sugarbaker PH (2003) Clinical presentation of peritoneal mesothelioma. Tumori 89:269–273
Husain AN, Colby TV, Ordóñez NG et al (2018) Guidelines for pathologic diagnosis of malignant mesothelioma 2017 update of the consensus statement from the international mesothelioma interest group. Arch Pathol Lab Med 142:89–108. https://doi.org/10.5858/arpa.2017-0124-RA
Cigognetti M, Lonardi S, Fisogni S et al (2015) BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations. Mod Pathol 28:1043–1057. https://doi.org/10.1038/modpathol.2015.65
Cristaudo A, Bonotti A, Simonini S et al (2011) Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma. J Thorac Oncol 6:1587–1593. https://doi.org/10.1097/JTO.0b013e31821e1c08
Hassan R, Remaley AT, Sampson ML et al (2006) Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res 12:447–453. https://doi.org/10.1158/1078-0432.CCR-05-1477
Baratti D, Kusamura S, Martinetti A et al (2007) Circulating CA125 in patients with peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol 14:500–508. https://doi.org/10.1245/s10434-006-9192-8
Weiss SW, Tavassoli FA (1988) Multicystic mesothelioma. An analysis of pathologic findings and biologic behavior in 37 cases. Am J Surg Pathol 12:737–746
Jouvin I, Dohan A, Gergi P, Pocard M (2014) Intra-abdominal benign multicystic peritoneal mesothelioma. J Visc Surg 151:155–157. https://doi.org/10.1016/j.jviscsurg.2013.12.014
Vara-Thorbeck C, Toscano-Mendez R (2002) Peritoneal cystic mesothelioma. Surg Endosc 16:220. https://doi.org/10.1007/s00464-001-0052-0
Chandramohan A, Thrower A, Shah N, Mohamed F (2017) Radiological predictors of complete cytoreduction in 59 patients with peritoneal mesothelioma treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a UK referral centre. Br J Radiol 90:20170361
Wong WL, Johns TA, Herlihy WG, Martin HL (2004) Best cases from the AFIP: multicystic mesothelioma. Radiographics 24:247–250. https://doi.org/10.1148/rg.241035068
Vallerie AM, Lerner JP, Wright JD, Baxi LV (2009) Peritoneal inclusion cysts: a review. Obstet Gynecol Surv 64:321–334. https://doi.org/10.1097/OGX.0b013e31819f93d4
Hasan AK, Sinclair DJ (1993) Case report: calcification in benign cystic peritoneal mesothelioma. Clin Radiol 48:66–67. https://doi.org/10.1016/s0009-9260(05)80113-8
Daya D, McCaughey WT (1990) Well-differentiated papillary mesothelioma of the peritoneum. A clinicopathologic study of 22 cases. Cancer 65:292–296. https://doi.org/10.1002/1097-0142(19900115)65:2%3c292::aid-cncr2820650218%3e3.0.co;2-w
Hoekman K, Tognon G, Risse EK, Bloemsma CA, Vermorken JB (1996) Well-differentiated papillary mesothelioma of the peritoneum: a separate entity. Eur J Cancer 32A:255–258. https://doi.org/10.1016/0959-8049(95)00574-9
Hoekstra AV, Riben MW, Frumovitz M, Liu J, Ramirez PT (2005) Well-differentiated papillary mesothelioma of the peritoneum: a pathological analysis and review of the literature. Gynecol Oncol 98(1):161–167. https://doi.org/10.1016/j.ygyno.2005.03.031
Lovell FA, Cranston PE (1990) Well-differentiated papillary mesothelioma of the peritoneum. AJR Am J Roentgenol 155:1245–1246. https://doi.org/10.2214/ajr.155.6.2122674
Sugarbaker PH, Acherman YIZ, Gonzalez-Moreno S et al (2002) Diagnosis and treatment of peritoneal mesothelioma: The Washington Cancer Institute experience. Semin Oncol 29:51–61. https://doi.org/10.1053/sonc.2002.30236
Sugarbaker PH, Welch LS, Mohamed F, Glehen O (2003) A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin N Am 12(605–621):xi. https://doi.org/10.1016/s1055-3207(03)00045-0
González-Moreno S, Yan H, Alcorn KW, Sugarbaker PH (2002) Malignant transformation of “benign” cystic mesothelioma of the peritoneum. J Surg Oncol 79:243–251. https://doi.org/10.1002/jso.10081
Sawh RN, Malpica A, Deavers MT et al (2003) Benign cystic mesothelioma of the peritoneum: a clinicopathologic study of 17 cases and immunohistochemical analysis of estrogen and progesterone receptor status. Hum Pathol 34:369–374. https://doi.org/10.1053/hupa.2003.31
Baratti D, Vaira M, Kusamura S et al (2010) Multicystic peritoneal mesothelioma: outcomes and patho-biological features in a multi-institutional series treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Surg Oncol 36:1047–1053. https://doi.org/10.1016/j.ejso.2010.08.130
Fennell DA, Gaudino G, O’Byrne KJ, Mutti L, van Meerbeeck J (2008) Advances in the systemic therapy of malignant pleural mesothelioma. Nat Clin Pract Oncol 5:136–147. https://doi.org/10.1038/ncponc1039
Vogelzang NJ, Rusthoven JJ, Symanowski J et al (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636–2644. https://doi.org/10.1200/JCO.2003.11.136
Simon GR, Verschraegen CF, Jänne PA et al (2008) Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial. J Clin Oncol 26:3567–3572. https://doi.org/10.1200/JCO.2007.15.2868
Alexander HR, Bartlett DL, Pingpank JF et al (2013) Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. Surgery 153:779–786. https://doi.org/10.1016/j.surg.2013.01.001
Yan TD, Edwards G, Alderman R, Marquardt CE, Sugarbaker PH (2007) Morbidity and mortality assessment of cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma–a prospective study of 70 consecutive cases. Ann Surg Oncol 14:515–525. https://doi.org/10.1245/s10434-006-9187-5
Baratti D, Kusamura S, Deraco M (2011) Diffuse malignant peritoneal mesothelioma: systematic review of clinical management and biological research. J Surg Oncol 103:822–831. https://doi.org/10.1002/jso.21787
Desantis M, Bernard J-L, Casanova V et al (2015) Morbidity, mortality, and oncological outcomes of 401 consecutive cytoreductive procedures with hyperthermic intraperitoneal chemotherapy (HIPEC). Langenbecks Arch Surg 400:37–48. https://doi.org/10.1007/s00423-014-1253-z
Helm JH, Miura JT, Glenn JA et al (2015) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. Ann Surg Oncol 22:1686–1693. https://doi.org/10.1245/s10434-014-3978-x
Robella M, Vaira M, Mellano A et al (2014) Treatment of diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery and HIPEC. Minerva Chir 69:9–15
Sugarbaker PH, Turaga KK, Alexander HR, Deraco M, Hesdorffer M (2016) Management of malignant peritoneal mesothelioma using cytoreductive surgery and perioperative chemotherapy. J Oncol Pract 12:928–935. https://doi.org/10.1200/JOP.2016.011908
Chandramohan A, Thrower A, Smith SA, Shah N, Moran B (2017) “PAUSE”: a method for communicating radiological extent of peritoneal malignancy. Clin Radiol 72:972–980. https://doi.org/10.1016/j.crad.2017.07.005
Jacquet P, Sugarbaker PH (1996) Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 82:359–374. https://doi.org/10.1007/978-1-4613-1247-5_23
Yan TD, Deraco M, Elias D et al (2011) A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database*. Cancer 117:1855–1863. https://doi.org/10.1002/cncr.25640
Low RN, Barone RM, Lucero J (2015) Comparison of MRI and CT for predicting the peritoneal cancer index (PCI) preoperatively in patients being considered for cytoreductive surgical procedures. Ann Surg Oncol 22:1708–1715. https://doi.org/10.1245/s10434-014-4041-7
Koh J-L, Yan TD, Glenn D, Morris DL (2009) Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis. Ann Surg Oncol 16:327–333. https://doi.org/10.1245/s10434-008-0234-2
Salo SAS, Lantto E, Robinson E et al (2020) Prognostic role of radiological peritoneal cancer index in malignant peritoneal mesothelioma: national cohort study. Sci Rep 10:13257. https://doi.org/10.1038/s41598-020-70044-8
Dubreuil J, Giammarile F, Rousset P et al (2017) The role of 18F-FDG-PET/ceCT in peritoneal mesothelioma. Nucl Med Commun 38:312–318. https://doi.org/10.1097/MNM.0000000000000649
Elekonawo FMK, Starremans B, Laurens ST et al (2019) Can [18F]F-FDG PET/CT be used to assess the pre-operative extent of peritoneal carcinomatosis in patients with colorectal cancer? Abdom Radiol (NY) 45(2):301–306. https://doi.org/10.1007/s00261-019-02268-w
Ballard DH, Mazaheri P, Oppenheimer DC et al (2020) Imaging of abdominal wall masses, masslike lesions, and diffuse processes. Radiographics 40:684–706. https://doi.org/10.1148/rg.2020190170
Spera LJ, Danforth RM, Hadad I (2018) Incisions and reconstruction approaches for large sarcomas. Transl Gastroenterol Hepatol. https://doi.org/10.21037/tgh.2018.10.07
Sangisetty SL, Miner TJ (2012) Malignant ascites: A Review of prognostic factors, pathophysiology and therapeutic measures. World J Gastrointest Surg 4:87–95. https://doi.org/10.4240/wjgs.v4.i4.87
Brandl A, Westbrook S, Nunn S et al (2020) Clinical and surgical outcomes of patients with peritoneal mesothelioma discussed at a monthly national multidisciplinary team video-conference meeting. BJS Open 4:260–267. https://doi.org/10.1002/bjs5.50256
Yan TD, Haveric N, Carmignani CP, Chang D, Sugarbaker PH (2005) Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy. Cancer 103:839–849. https://doi.org/10.1002/cncr.20836
Chandramohan A, Thrower A (2019) Imaging in peritoneal malignancy. In: Cecil T, Bunni J, Mehta A (eds) A practical guide to peritoneal malignancy. CRC Press, Boca Raton
Elliott HS, Metser U, de Perrot M et al (2018) 18F-FDG PET/CT in the management of patients with malignant pleural mesothelioma being considered for multimodality therapy: experience of a tertiary referral center. Br J Radiol 91:20170814. https://doi.org/10.1259/bjr.20170814
No funding was received to assist with the preparation of this manuscript.
Ethics approval and consent to participate
Consent for publication
The authors have no financial or proprietary interests in any material discussed in this article.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Chandramohan, A., Shah, N., Thrower, A. et al. Communicating imaging findings in peritoneal mesothelioma: the impact of ‘PAUSE’ on surgical decision-making. Insights Imaging 12, 174 (2021). https://doi.org/10.1186/s13244-021-01118-y
- Peritoneal mesothelioma
- Complete cytoreduction
- Radiological peritoneal cancer index